Generation of stable PDX derived cell lines using conditional reprogramming.

Area of Science:

• Oncology
• Translational Research
• Biotechnology

Background:

• Developing effective cancer therapeutics is challenged by the lack of clinically predictive preclinical models.
• Patient-derived xenograft (PDX) models offer translational value but face limitations, particularly in sustained in vitro growth.

Discussion:

• Conditional Reprogramming (CR) cell technology was employed to establish stable cell lines from patient-derived xenograft (PDX) tumors.
• These CR-PDX cell lines retained parental driver mutations and allele frequency, demonstrating genetic stability without clonal drift.
• The CR-PDX models proved suitable for high-throughput chemosensitivity screening and in vitro genetic knockdown studies.

Key Insights:

• CR technology successfully generated stable explant cell lines (CR-PDX) from human lung and ovarian PDX tumors.
• Re-implantation of CR-PDX cells resulted in tumors that mirrored the growth kinetics, histology, and drug responses of the parental PDX tumors.
• CR technology allows for the expansion of PDX cells in vitro, preserving fundamental biological properties for downstream applications.

Outlook:

• This CR-PDX platform enhances the generation of physiologically relevant and predictive preclinical models for cancer drug discovery.
• Utilizing CR-PDX models can reduce animal usage and study costs by enabling in vitro expansion and reducing variability in in vivo studies.
• The developed methods provide a robust platform to accelerate the identification and validation of novel cancer therapeutics.